###begin article-title 0
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In Vivo</italic>
###xml 82 86 <span type="species:ncbi:10090">Mice</span>
###xml 145 149 <span type="species:ncbi:10090">Mice</span>
In Vivo Turnover of Tau and APP Metabolites in the Brains of Wild-Type and Tg2576 Mice: Greater Stability of sAPP in the beta-Amyloid Depositing Mice
###end article-title 0
###begin p 1
Conceived and designed the experiments: JMC PMM. Performed the experiments: JMC MJM JDB NSD JHC PMM. Analyzed the data: JMC JHC EL YM EP PMM. Contributed reagents/materials/analysis tools: EL YM EP PMM. Wrote the paper: JMC EP PMM.
###end p 1
###begin p 2
Current address: Neurodegeneration Research, GlaxoSmithKline, Shanghai, China
###end p 2
###begin p 3
###xml 144 151 144 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 232 237 <span type="species:ncbi:10090">mouse</span>
###xml 340 345 <span type="species:ncbi:10090">mouse</span>
###xml 445 450 <span type="species:ncbi:10090">mouse</span>
###xml 572 578 <span type="species:ncbi:10090">murine</span>
###xml 601 606 <span type="species:ncbi:9606">human</span>
###xml 652 656 <span type="species:ncbi:10090">mice</span>
###xml 828 832 <span type="species:ncbi:10090">mice</span>
###xml 981 985 <span type="species:ncbi:10090">mice</span>
###xml 1149 1154 <span type="species:ncbi:10090">mouse</span>
###xml 1341 1345 <span type="species:ncbi:10090">mice</span>
The metabolism of the amyloid precursor protein (APP) and tau are central to the pathobiology of Alzheimer's disease (AD). We have examined the in vivo turnover of APP, secreted APP (sAPP), Abeta and tau in the wild-type and Tg2576 mouse brain using cycloheximide to block protein synthesis. In spite of overexpression of APP in the Tg2576 mouse, APP is rapidly degraded, similar to the rapid turnover of the endogenous protein in the wild-type mouse. sAPP is cleared from the brain more slowly, particularly in the Tg2576 model where the half-life of both the endogenous murine and transgene-derived human sAPP is nearly doubled compared to wild-type mice. The important Abeta degrading enzymes neprilysin and IDE were found to be highly stable in the brain, and soluble Abeta40 and Abeta42 levels in both wild-type and Tg2576 mice rapidly declined following the depletion of APP. The cytoskeletal-associated protein tau was found to be highly stable in both wild-type and Tg2576 mice. Our findings unexpectedly show that of these various AD-relevant protein metabolites, sAPP turnover in the brain is the most different when comparing a wild-type mouse and a beta-amyloid depositing, APP overexpressing transgenic model. Given the neurotrophic roles attributed to sAPP, the enhanced stability of sAPP in the beta-amyloid depositing Tg2576 mice may represent a neuroprotective response.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 246 249 240 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Glenner1">[1]</xref>
###xml 368 371 362 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-GrundkeIqbal1">[2]</xref>
###xml 617 620 596 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Hartmann1">[3]</xref>
###xml 964 967 931 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Hardy1">[4]</xref>
###xml 1123 1126 1086 1089 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Sisodia1">[5]</xref>
###xml 1680 1683 1599 1602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Hardy1">[4]</xref>
The brain accumulation of abnormal proteins is a common hallmark of multiple neurodegenerative diseases. Alzheimer's disease (AD) brains are characterized by extracellular aggregates of the small (40 and 42 residues) beta-amyloid peptide (Abeta) [1], and intraneuronal neurofibrillary tangles, composed of hyperphosphorylated tau assembled in paired helical filaments [2]. Abeta is generated by proteolysis of the approximately100-kDa amyloid precursor protein (APP), a broadly expressed type-1 transmembrane protein that is found primarily in the trans-Golgi network, endocytic compartments, and at the cell surface [3]. beta-Cleavage of APP, mediated by BACE1, occurs within the luminal/extracellular domain of APP and generates two APP fragments: a large, soluble amino-terminal fragment (sAPPbeta) that is secreted from the cell and a transmembrane, carboxyl-terminal fragment (betaCTF) containing the whole Abeta peptide that remains associated with the cell [4]. An alternative pathway involves the cleavage of APP 16 residues downstream of this site at the alpha-cleavage site, which is mediated by metalloproteases [5]. Like beta-cleavage, alpha-cleavage generates an sAPP fragment (sAPPalpha) that is secreted from the cell and an alphaCTF that remains membrane-associated. alpha-Cleavage occurs within the Abeta peptide sequence and as such prevents the generation of Abeta from a given APP molecule. Abeta is generated from the betaCTF by an intramembrane cleavage (mediated by the presenilin gamma-secretase complex) that occurs primarily at 40 residues, and to a lesser extent at 42 residues, downstream from the beta-cleavage site, releasing Abeta1-40 and Abeta1-42 [4].
###end p 5
###begin p 6
###xml 210 213 210 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Gralle1">[6]</xref>
###xml 313 316 306 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Cole1">[7]</xref>
###xml 317 320 310 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Golde1">[9]</xref>
###xml 549 553 536 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Iwata1">[10]</xref>
###xml 555 559 542 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Qiu1">[11]</xref>
###xml 605 612 592 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 647 651 634 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-DeStrooper1">[12]</xref>
###xml 1010 1017 994 1001 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1416 1420 1400 1404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Cirrito1">[13]</xref>
###xml 1422 1426 1406 1410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Savage1">[14]</xref>
###xml 1630 1637 1614 1621 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 1659 1663 <span type="species:ncbi:10090">mice</span>
While much is known about the proteolytic processes that lead to the generation of these APP metabolites, their subsequent metabolism and function(s) in the central nervous system (CNS) are not as well defined [6]. APP that is not cleaved at the alpha- or beta-sites can be degraded through the lysosomal pathway [7]-[9]. Abeta accumulation in the brain during AD is dependent on the misbalance of production and turnover of this peptide, with neprilysin and insulin degrading enzyme (IDE) known to be important Abeta degrading enzymes in the brain [10], [11]. The turnover of the secreted sAPP fragments in vivo has not been extensively examined [12], and, unlike APP, cannot be assessed using cell culture systems where sAPP is simply secreted into the growth media. Understanding the turnover of proteins in the brain that play a central role in neurodegenerative diseases, such as APP and tau, can help to explain why a protein/peptide fragment, such as Abeta, accumulates. Additionally, understanding the in vivo turnover of APP metabolites and tau in the normal, intact brain is an important consideration when developing therapeutic strategies directed at altering their levels. In the case of APP, the fragments that are generated may have important physiological functions related to their abundance and regulation in the CNS. For example, sAPP is thought to have neuroprotective and neurotrophic functions [13], [14], which would be unique to the CNS and dependent upon its stability in the brain. In order to directly examine the turnover of endogenous APP, APP metabolites, and tau in an intact brain, we have blocked de novo protein synthesis in mice and examined the stability of these proteins over time.
###end p 6
###begin title 7
Results
###end title 7
###begin p 8
###xml 178 194 175 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007134-g001">Figure 1A and 1B</xref>
###xml 442 446 427 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Hsiao1">[15]</xref>
###xml 457 466 442 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007134-g001">Figure 1A</xref>
###xml 119 123 <span type="species:ncbi:10090">mice</span>
###xml 257 261 <span type="species:ncbi:10090">mice</span>
###xml 330 335 <span type="species:ncbi:9606">human</span>
###xml 533 538 <span type="species:ncbi:10090">mouse</span>
###xml 647 651 <span type="species:ncbi:10090">mice</span>
###xml 836 840 <span type="species:ncbi:10090">mice</span>
###xml 882 886 <span type="species:ncbi:10090">mice</span>
###xml 985 989 <span type="species:ncbi:10090">mice</span>
Following treatment with cycloheximide, we examined by Western blotting APP holoprotein levels in the brains of Tg2576 mice with beta-amyloid deposits and wild-type littermates. Figure 1A and 1B show that APP levels rapidly declined in Tg2576 and wild-type mice following protein synthesis inhibition. The initial turnover of the human Swedish APP in the Tg2576 model, which is overexpressed at approximately6-fold of the endogenous protein ([15]; see also Figure 1A), is similar to the turnover of the endogenous APP in a wild-type mouse, with approximately40% of the pre-existing APP degraded within the first hour. In both Tg2576 and wild-type mice, a portion of the initial APP was found to persist up to 23 hours following the inhibition of protein synthesis, with a greater amount of the initial APP pool persisting in the Tg2576 mice (approximately50%) than in the wild-type mice (approximately30%); p<0.001, two-way ANOVA comparing the APP turnover in the Tg2576 and wild-type mice.
###end p 8
###begin title 9
###xml 48 53 <span type="species:ncbi:10090">mouse</span>
Turnover of APP and sAPP in 16-month-old Tg2576 mouse and wild-type brains following cycloheximide treatment.
###end title 9
###begin p 10
###xml 356 360 353 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Garner1">[52]</xref>
###xml 1795 1802 1758 1765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Methods</xref>
###xml 108 112 <span type="species:ncbi:10090">mice</span>
###xml 160 165 <span type="species:ncbi:9606">human</span>
###xml 195 199 <span type="species:ncbi:10090">mice</span>
###xml 215 221 <span type="species:ncbi:10090">murine</span>
###xml 239 243 <span type="species:ncbi:10090">mice</span>
###xml 420 425 <span type="species:ncbi:10090">mouse</span>
###xml 581 585 <span type="species:ncbi:10090">mice</span>
###xml 725 729 <span type="species:ncbi:10090">mice</span>
###xml 845 849 <span type="species:ncbi:10090">mice</span>
###xml 851 856 <span type="species:ncbi:9606">Human</span>
###xml 962 968 <span type="species:ncbi:10090">murine</span>
###xml 1282 1286 <span type="species:ncbi:10090">mice</span>
###xml 1455 1459 <span type="species:ncbi:10090">mice</span>
###xml 1536 1540 <span type="species:ncbi:10090">mice</span>
###xml 1570 1576 <span type="species:ncbi:10090">murine</span>
###xml 1684 1688 <span type="species:ncbi:10090">mice</span>
Western blotting is shown of total proteins isolated from brain tissue following cycloheximide treatment of mice for the indicated times. (A) Transgene-derived human and endogenous APP in Tg2576 mice and endogenous murine APP in wild-type mice was detected with the anti-C-terminal APP antibody C1/6.1; beta-tubulin, which is known to be stable in the CNS [52], is shown in control Western blots. An untreated wild-type mouse (wt) is included in the Tg2576 analysis to show the increased APP expression in this model. (B) Quantification of APP turnover in the Tg2576 and wild-type mice normalized to the band density without cycloheximide treatment; two-way ANOVA was used to compare APP turnover in the Tg2576 and wild-type mice (p<0.001). (C) Following the indicated cycloheximide treatment times, sAPP total was detected with 22C11 in Tg2576 mice. Human sAPPalpha and sAPPbeta were detected by Western blotting with 6E10 and 6A1, respectively, and endogenous murine sAPPalpha and sAPPbeta were detected by Western blotting with m3.2 and 242, respectively. Non-specific bands detected by the affinity purified polyclonal 242 are shown by the APP knockout brain homogenate. (D) Levels of endogenous sAPP total, sAPPalpha and sAPPbeta were detected by Western blotting in wild-type mice following cycloheximide treatment as described above. The graphic representations in (E) compare the quantification of the levels of sAPP total in Tg2576 and wild-type mice (p<0.001). In (F), the turnover of the indicated sAPP species in the Tg2576 mice is shown (p<0.001, comparing murine sAPPalpha to the other sAPP species). In (G), the levels of endogenous sAPPalpha and sAPPbeta in wild-type mice is shown (p>0.5). Throughout, quantifications are from two experiments (mean +/- SEM) as specified in the Methods section.
###end p 10
###begin p 11
###xml 274 283 274 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007134-g001">Figure 1C</xref>
###xml 318 327 318 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007134-g001">Figure 1D</xref>
###xml 488 492 476 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Caille1">[16]</xref>
###xml 495 504 483 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007134-g001">Figure 1E</xref>
###xml 751 760 739 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007134-g001">Figure 1C</xref>
###xml 831 840 819 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007134.s001">Figure S1</xref>
###xml 136 141 <span type="species:ncbi:9606">human</span>
###xml 146 151 <span type="species:ncbi:10090">mouse</span>
###xml 299 303 <span type="species:ncbi:10090">mice</span>
###xml 403 407 <span type="species:ncbi:10090">mice</span>
###xml 446 450 <span type="species:ncbi:10090">mice</span>
###xml 592 596 <span type="species:ncbi:10090">mice</span>
###xml 647 651 <span type="species:ncbi:10090">mice</span>
###xml 805 810 <span type="species:ncbi:10090">mouse</span>
Next, we examined the levels of sAPP in the brain following cycloheximide treatment. Using 22C11 antibody to detect all sAPP fragments, human and mouse and following cycloheximide treatment, it was found that sAPP total is cleared from the brain in the Tg2576 (top panel of Figure 1C) and wild-type mice (top panel of Figure 1D). The half-life for sAPP total was found to be more than 7 hours in Tg2576 mice and approximately4 hours in wild-type mice (calculated as a first-order process [16]) (Figure 1E); p<0.001, two-way ANOVA comparing the sAPP total turnover in the Tg2576 and wild-type mice. Initial sAPP total levels in the brain of Tg2576 mice were increased relative to wild type, as is expected given increased APP expression (see top panel Figure 1C). Moreover, sAPP itself is more abundant in mouse brain than APP (see Figure S1, lower panel E), consistent with the sAPP species having a longer half-life in the brain than APP.
###end p 11
###begin p 12
###xml 48 55 48 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 160 169 153 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007134-g001">Figure 1C</xref>
###xml 351 360 322 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007134-g001">Figure 1F</xref>
###xml 623 632 574 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007134-g001">Figure 1E</xref>
###xml 654 663 605 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007134-g001">Figure 1D</xref>
###xml 735 742 679 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 779 788 711 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007134-g001">Figure 1G</xref>
###xml 891 900 823 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007134-g001">Figure 1E</xref>
###xml 107 111 <span type="species:ncbi:10090">mice</span>
###xml 142 147 <span type="species:ncbi:9606">human</span>
###xml 152 158 <span type="species:ncbi:10090">murine</span>
###xml 186 190 <span type="species:ncbi:10090">mice</span>
###xml 208 214 <span type="species:ncbi:10090">murine</span>
###xml 297 303 <span type="species:ncbi:10090">murine</span>
###xml 314 319 <span type="species:ncbi:9606">human</span>
###xml 335 340 <span type="species:ncbi:9606">human</span>
###xml 427 433 <span type="species:ncbi:10090">murine</span>
###xml 538 543 <span type="species:ncbi:10090">mouse</span>
###xml 648 652 <span type="species:ncbi:10090">mice</span>
###xml 686 692 <span type="species:ncbi:10090">murine</span>
###xml 885 889 <span type="species:ncbi:10090">mice</span>
To further explore potential differences in the in vivo half-life of sAPP, we differentiated in the Tg2576 mice sAPPalpha from sAPPbeta, both human and murine (Figure 1C). In the Tg2576 mice, the turnover of murine sAPPalpha (sAPPalpha t(1/2) >7 hours) was found to be slower than the turnover of murine sAPPbeta, human sAPPalpha, and human sAPPbeta (Figure 1F; t(1/2) approximately5-6 hours) (p<0.001, two-way ANOVA comparing murine sAPPalpha to the other sAPP species), although the relative stability of all sAPP species in the Tg2576 mouse brain is in agreement with the slow turnover of sAPP total seen in this model (Figure 1E). In wild-type mice (Figure 1D), both the endogenous murine sAPPalpha and sAPPbeta were found to have in vivo half-lives of approximately4 hours (Figure 1G), in close agreement with the turnover seen for sAPP total detected with 22C11 in the wild-type mice (Figure 1E). No breakdown products were specifically detected by the antibody against APP (C1/6.1) or the different sAPP antibodies in these Western blot analyses.
###end p 12
###begin p 13
###xml 297 306 288 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007134-g002">Figure 2A</xref>
###xml 327 336 318 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007134-g002">Figure 2B</xref>
###xml 499 503 487 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-MeyerLuehmann1">[17]</xref>
###xml 879 888 855 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007134-g002">Figure 2C</xref>
###xml 1178 1187 1127 1136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007134-g002">Figure 2D</xref>
###xml 291 295 <span type="species:ncbi:10090">mice</span>
###xml 321 325 <span type="species:ncbi:10090">mice</span>
###xml 538 542 <span type="species:ncbi:10090">mice</span>
###xml 809 813 <span type="species:ncbi:10090">mice</span>
###xml 928 932 <span type="species:ncbi:10090">mice</span>
###xml 1036 1040 <span type="species:ncbi:10090">mice</span>
###xml 1172 1176 <span type="species:ncbi:10090">mice</span>
###xml 1299 1303 <span type="species:ncbi:10090">mice</span>
###xml 1404 1408 <span type="species:ncbi:10090">mice</span>
###xml 1504 1508 <span type="species:ncbi:10090">mice</span>
Prior to examining the clearance of Abeta in the brain, we determined the stability of two Abeta degrading enzymes: neprilysin and insulin degrading enzyme (IDE). The levels of these important Abeta degrading enzymes do not decline rapidly following cycloheximide treatment in either Tg2576 mice (Figure 2A) or wild-type mice (Figure 2B), and both proteases were readily detected following 23 hours of cycloheximide treatment. Plaque-associated Abeta is thought to be highly stable within the brain [17]. Total Abeta levels in the Tg2576 mice, determined by formic acid extraction of plaque Abeta, varied between animals independently of cycloheximide treatment time (data not shown). However, the pool of soluble Abeta measured by DEA extraction normalized to formic-acid extractable Abeta in a given Tg2576 mice was found to rapidly decrease following cycloheximide treatment (Figure 2C). The soluble Abeta pool in the Tg2576 mice decreased by approximately50% at maximum, suggesting that soluble Abeta in the beta-amyloid depositing mice may be in equilibrium with plaque-associated Abeta. We also examined DEA extractable, soluble endogenous Abeta levels in wild-type mice (Figure 2D). Brain Abeta40 and Abeta42 levels decreased rapidly, at a rate similar to that of soluble Abeta in the Tg2576 mice, and consistent with the rapid depletion of precursor APP in the brain. In comparison to the Tg2576 mice, less of the initial Abeta remained after 23 hours of cycloheximide treatment in the wild-type mice.
###end p 13
###begin title 14
###xml 82 87 <span type="species:ncbi:10090">mouse</span>
Turnover of neprilysin, IDE and Abeta levels in 16-month-old Tg2576 and wild-type mouse brains following cycloheximide treatment.
###end title 14
###begin p 15
###xml 85 89 <span type="species:ncbi:10090">mice</span>
###xml 191 196 <span type="species:ncbi:9606">human</span>
###xml 227 231 <span type="species:ncbi:10090">mice</span>
###xml 420 424 <span type="species:ncbi:10090">mice</span>
Neprilysin and IDE turnover is shown by Western blotting in Tg2576 (A) and wild-type mice (B); beta-tubulin is shown as a control. (C) The ratio of DEA-extractable to formic acid-extractable human Abeta40 and Abeta42 in Tg2576 mice were measured by sandwich ELISA at the indicated times following cycloheximide treatment (mean +/- SEM). (D) Turnover of endogenous DEA-extractable Abeta40 and Abeta42 levels in wild-type mice (mean +/- SEM).
###end p 15
###begin p 16
###xml 27 34 27 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 277 293 277 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007134-g003">Figure 3A and 3B</xref>
###xml 847 863 823 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007134-g003">Figure 3A and 3C</xref>
###xml 1130 1139 1094 1103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007134-g003">Figure 3C</xref>
###xml 1196 1200 1160 1164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Barney1">[18]</xref>
###xml 1281 1285 1245 1249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Planel1">[19]</xref>
###xml 1287 1291 1251 1255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Planel2">[20]</xref>
###xml 1982 1991 1904 1913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007134-g003">Figure 3D</xref>
###xml 2306 2315 2222 2231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007134-g003">Figure 3E</xref>
###xml 2393 2400 2309 2316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 2565 2574 2481 2490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007134-g003">Figure 3D</xref>
###xml 67 71 <span type="species:ncbi:10090">mice</span>
###xml 195 199 <span type="species:ncbi:10090">mice</span>
###xml 372 376 <span type="species:ncbi:10090">mice</span>
###xml 400 404 <span type="species:ncbi:10090">mice</span>
###xml 616 620 <span type="species:ncbi:10090">mice</span>
###xml 761 765 <span type="species:ncbi:10090">mice</span>
###xml 923 927 <span type="species:ncbi:10090">mice</span>
###xml 951 955 <span type="species:ncbi:10090">mice</span>
###xml 1124 1128 <span type="species:ncbi:10090">mice</span>
###xml 1240 1244 <span type="species:ncbi:10090">mice</span>
###xml 1385 1389 <span type="species:ncbi:10090">mice</span>
###xml 1449 1453 <span type="species:ncbi:10090">mice</span>
###xml 1498 1502 <span type="species:ncbi:10090">mice</span>
###xml 1663 1667 <span type="species:ncbi:10090">mice</span>
###xml 1767 1771 <span type="species:ncbi:10090">mice</span>
###xml 1875 1879 <span type="species:ncbi:10090">mice</span>
Finally, we determined the in vivo turnover rate of tau. In Tg2576 mice, the levels of tau protein (T57120) were unchanged with cycloheximide treatment over 23 hours. Similarly, in the wild-type mice levels of tau protein were unchanged following protein synthesis inhibition (Figure 3A and 3B). In contrast, a greater upward shift in the mobility of tau in the wild-type mice compared to the Tg2576 mice following cycloheximide treatment is suggestive of a robust increase in tau phosphorylation. Consistent with this idea, the levels of phosphorylated-tau detected by PHF-1 dramatically increased in the wild-type mice following protein synthesis inhibition (approximately3.4-times at 23 hours), whereas the change in PHF-1 signal from baseline in the Tg2576 mice following cycloheximide treatment was less (approximately1.5-times at 23 hours) (Figure 3A and 3C). While the initial PHF-1 signal was less in the wild-type mice compared to the Tg2576 mice (Tg2576 approximately2.2-times wild-type without treatment), after 23 hours of protein-synthesis inhibition the level of PHF-1 reactivity was similar in both groups of mice (Figure 3C). Cycloheximide treatment is known to cause hypothermia [18], and a decrease in body temperature in mice increases the levels of phospho-tau [19], [20]. To determine whether cycloheximide-treatment increases tau phosphorylation in the wild-type mice primarily as the result of a decrease in body temperature, mice housed at room temperature were compared to mice housed at 34degreesC. When housed for 19 hours at 22degreesC following cycloheximide treatment body temperature decreased by 4.8+/-1.1degreesC (n = 6), whereas mice housed at 34degreesC showed a smaller drop in body temperature (2.3+/-0.4degreesC; n = 6). Control mice showed no change in body temperature when housed at 34degreesC. When compared by Western blotting, the mice housed at 34degreesC had less of an increase in phospho-tau levels following cycloheximide treatment (Figure 3D). Primary neurons maintained at 37degreesC showed a small and transient increase in phospho-tau following cycloheximide treatment that was also reflected in the appearance of a slower migrating band in the total tau Western blot, possibly due to differential turnover of the relevant tau kinases and phosphatases (Figure 3E). Nevertheless, the reduction in cycloheximide-dependent tau phosphorylation in vivo when body temperature is maintained suggests that the bulk of the increase in tau phosphorylation over a longer period results from a decrease in body temperature (Figure 3D).
###end p 16
###begin title 17
Metabolism of tau following protein synthesis inhibition.
###end title 17
###begin p 18
###xml 299 307 299 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007134-g001">Figure 1</xref>
###xml 216 221 <span type="species:ncbi:10090">mouse</span>
###xml 245 250 <span type="species:ncbi:10090">mouse</span>
###xml 416 420 <span type="species:ncbi:10090">mice</span>
###xml 551 555 <span type="species:ncbi:10090">mice</span>
###xml 642 646 <span type="species:ncbi:10090">mice</span>
###xml 760 765 <span type="species:ncbi:10090">mouse</span>
###xml 811 815 <span type="species:ncbi:10090">mice</span>
(A) Western blots are shown using an antibody that recognizes tau independent of its phosphorylation status (T57120, top panels) and an antibody that detects a phospho-epitope on tau (PHF-1, bottom panels) in Tg2576 mouse brain and in wild-type mouse brain. Total brain proteins were analyzed as in Figure 1. (B) Change in the intensity of the T57120 signal following cycloheximide treatment in Tg2576 and wild-type mice is shown (mean +/- SEM). (C) Change in the intensity of the PHF1 signal following cycloheximide treatment in Tg2576 and wild-type mice is shown (mean+/-SEM). Signal intensity is normalized to the PHF1 signal in wild-type mice without treatment (inserted Western blot). (D) Tau levels detected with T57120 and PHF-1 antibodies in wild-type mouse brain following cycloheximide treatment when mice were housed at ambient temperature (22degreesC) or at 34degreesC for 19 hours. beta-tubulin is shown as a loading control. (E) Tau levels in primary neurons were detected by Western blotting with T57120 and PHF-1 antibodies after cycloheximide treatment as indicated. beta-tubulin is shown as a loading control.
###end p 18
###begin title 19
Discussion
###end title 19
###begin p 20
###xml 340 344 340 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Gold1">[21]</xref>
###xml 548 552 545 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Hsiao1">[15]</xref>
###xml 824 828 818 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Radde1">[22]</xref>
###xml 938 945 932 939 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 308 312 <span type="species:ncbi:10090">mice</span>
###xml 479 483 <span type="species:ncbi:10090">mice</span>
###xml 529 534 <span type="species:ncbi:10090">mouse</span>
Global protein-synthesis inhibition can be used to determine the stability of proteins in an animal, and is appealing when examining protein turnover in the CNS as the protein-synthesis inhibitor cycloheximide readily passes the blood-brain barrier and the conditions for CNS-protein-synthesis inhibition in mice have been well established [21]. Using this, we examined in the brain the metabolic turnover of two proteins key to AD pathobiology, tau and APP, comparing wild-type mice with a transgenic beta-amyloid depositing AD mouse model Tg2576 [15]. The turnover for a metabolite such as the secreted sAPP species as well as extracellular Abeta cannot be extrapolated from a cell culture system, and can only be determined in the intact brain. Moreover, determining the impact of plaque pathology and associated gliosis [22] on the turnover rate for tau, APP and other APP metabolites such as sAPP also necessarily requires an intact in vivo system.
###end p 20
###begin p 21
###xml 235 239 235 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Mercken1">[23]</xref>
###xml 481 488 481 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 577 581 577 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Alonso1">[24]</xref>
###xml 583 587 583 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-GrundkeIqbal2">[25]</xref>
###xml 884 888 884 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Planel1">[19]</xref>
###xml 890 894 890 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Planel2">[20]</xref>
###xml 1019 1023 1019 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Tomidokoro1">[26]</xref>
###xml 1024 1028 1024 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Savage2">[28]</xref>
###xml 91 95 <span type="species:ncbi:10090">mice</span>
###xml 201 206 <span type="species:ncbi:10090">mouse</span>
###xml 349 353 <span type="species:ncbi:10090">mice</span>
###xml 632 636 <span type="species:ncbi:10090">mice</span>
###xml 951 955 <span type="species:ncbi:10090">mice</span>
###xml 1014 1018 <span type="species:ncbi:10090">mice</span>
Our finding that tau is a highly stable protein in the brains of both wild-type and Tg2576 mice is in agreement with a report of tau protein persisting for more than 30 days during transport along the mouse optic nerve from the retina [23], and suggests that tau remains long-lived once delivered to the distal neurite. In both wild-type and Tg2576 mice, the total levels of tau protein were unchanged with as long as 23 hours of cycloheximide treatment, and this stability of tau in vivo may predispose it to accumulation such as occurs in AD with paired helical filament tau [24], [25]. Unexpectedly, both in wild-type and Tg2576 mice the levels of phosphorylated-tau increased following inhibition of protein synthesis, apparently due to hypothermia. Hypothermia is a powerful enhancer of tau phosphorylation through its effects on the balance of kinase and phosphatase activities [19], [20], although this effect was less pronounced in the Tg2576 mice, possibly because baseline phospho-tau is higher in these mice [26]-[28].
###end p 21
###begin p 22
###xml 182 186 182 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-LeBlanc1">[29]</xref>
###xml 321 325 321 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Koo1">[30]</xref>
###xml 392 397 392 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 399 403 399 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Lyckman1">[31]</xref>
###xml 702 706 <span type="species:ncbi:10090">mice</span>
###xml 771 775 <span type="species:ncbi:10090">mice</span>
###xml 831 846 <span type="species:ncbi:10090">transgenic mice</span>
###xml 910 914 <span type="species:ncbi:10090">mice</span>
The rapid turnover of endogenous APP following protein synthesis inhibition in the brain is consistent with what has been reported by pulse-chase of cultured rodent neurons and glia [29]. APP is transported by rapid anterograde transport in neurons, with most of its processing apparently occurring at the distal neurite [30]. Following metabolic labelling of retinal ganglion cells, Lyckman et al. [31] found that APP, once transported to the presynaptic termini, had a half-life of less than 4 hours. Consistent with these reports, our findings present a global picture of APP metabolism in the brain showing a rapid bulk-turnover of the holoprotein, both under normal expression levels in wild-type mice and with APP overexpression and plaque pathology in aged Tg2576 mice. Indeed, in spite of the greater APP expression in the transgenic mice the initial turnover of APP is similar in Tg2576 and wild-type mice, although a greater proportion of APP stably persists following extended cycloheximide treatment in the APP overexpressing transgenics.
###end p 22
###begin p 23
###xml 62 66 62 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Bass1">[32]</xref>
###xml 78 82 78 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Rudick1">[33]</xref>
###xml 331 335 331 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Caille1">[16]</xref>
###xml 662 666 662 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Araki1">[34]</xref>
###xml 667 671 667 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Ring1">[39]</xref>
###xml 843 847 840 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-TapiaArancibia1">[40]</xref>
###xml 1002 1006 996 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Araki1">[34]</xref>
###xml 1007 1011 1001 1005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Roch1">[38]</xref>
###xml 1341 1345 1325 1329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Citron1">[41]</xref>
###xml 1347 1351 1331 1335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Cai1">[42]</xref>
###xml 30 35 <span type="species:ncbi:10090">mouse</span>
###xml 178 183 <span type="species:ncbi:10090">mouse</span>
###xml 417 422 <span type="species:ncbi:10090">mouse</span>
###xml 656 661 <span type="species:ncbi:10090">mouse</span>
###xml 715 719 <span type="species:ncbi:10090">mice</span>
###xml 742 746 <span type="species:ncbi:10090">mice</span>
###xml 1083 1087 <span type="species:ncbi:10090">mice</span>
###xml 1183 1189 <span type="species:ncbi:10090">murine</span>
###xml 1286 1291 <span type="species:ncbi:9606">human</span>
###xml 1407 1411 <span type="species:ncbi:10090">mice</span>
###xml 1738 1743 <span type="species:ncbi:10090">mouse</span>
###xml 1833 1838 <span type="species:ncbi:9606">human</span>
###xml 1843 1849 <span type="species:ncbi:10090">murine</span>
###xml 1869 1875 <span type="species:ncbi:10090">murine</span>
###xml 2107 2112 <span type="species:ncbi:10090">mouse</span>
The bulk flow of the CSF in a mouse brain, measured by inulin [32] or albumin [33] transport, is approximately 2-3 hours, which is similar to the turnover of sAPP in a wild-type mouse brain and suggests that this soluble APP metabolite may diffuse in the brain along with the bulk flow of CSF as a major pathway for its catabolism [16]. However, the turnover of sAPP in the brain was found to be slower in the Tg2576 mouse than in a wild-type animal. sAPP has been shown to support cell survival, neurite outgrowth, synaptogenesis, synaptic plasticity, can modify the response of neurons to injury, and can substantially rescue CNS deficits in an APP null mouse [34]-[39]. The increased stability of sAPP in Tg2576 mice relative to wild-type mice is consistent with a greater need for neurotrophic support in the beta-amyloid containing brain [40] and may reflect an ongoing role for sAPP in supporting neuron function in the context of beta-amyloid toxicity, neuron stress, and inflammatory responses [34]-[38]. In the context of the greater overall stability of sAPP in the Tg2576 mice, substantial differences were also seen in the turnover of the specific sAPP species, with the murine sAPPalpha the most stable of the sAPP species. Given that the Swedish mutation in the transgene human APP drives beta-cleavage and sAPPbeta production [41], [42], the disproportionate levels of sAPPbeta in the Tg2576 mice may impact the turnover of the relatively underrepresented sAPPalpha. Additionally, Abeta pathology may alter the turnover of sAPPalpha through an interaction in the brain parenchymal between the sequence homology at the C-terminus of sAPPalpha with the N-terminus of Abeta. Additionally, overexpression of sAPP in the Tg2576 mouse may overload the degradation pathway, although the differences in the metabolism between human and murine sAPP species, with murine sAPPalpha showing the longest half-life, suggests that species differences and/or differences in the handling of the Swedish-mutation-containing sAPP fragments also play a role in brain sAPP turnover in the beta-amyloid depositing mouse model.
###end p 23
###begin p 24
###xml 292 296 261 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Cirrito1">[13]</xref>
###xml 316 320 285 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Savage1">[14]</xref>
###xml 1433 1440 1359 1366 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 734 738 <span type="species:ncbi:10090">mice</span>
###xml 1088 1092 <span type="species:ncbi:10090">mice</span>
###xml 1360 1375 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1512 1516 <span type="species:ncbi:10090">mice</span>
###xml 1621 1625 <span type="species:ncbi:10090">mice</span>
###xml 1715 1730 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1767 1771 <span type="species:ncbi:10090">mice</span>
We find that endogenous Abeta, both Abeta40 and Abeta42, is rapidly degraded following cycloheximide treatment and the depletion of pre-existing APP. Following gamma-secretase inhibition, Abeta microdialysis measurements have given a half-life for extracellular Abeta of approximately2 hours [13], and Savage et al. [14] have shown that shifting APP processing to the alpha-secretase pathway resulted in a decline in total brain Abeta with a half-life between 1 and 2.5 hours. Our findings, which used a different experimental approach that does not specifically alter an APP cleavage step, further support the conclusion that Abeta is rapidly cleared from the normal brain. Soluble Abeta in the beta-amyloid plaque containing Tg2576 mice showed a similar and rapid decrease following cessation of protein synthesis, again with Abeta40 and Abeta42 turnover being similar. These findings indicate that the soluble Abeta pool in a brain containing beta-amyloid plaque is similarly accessible to degradation as is soluble Abeta in a normal brain. The reduction plateau reached in the Tg2576 mice for soluble Abeta, which is likely to be in equilibrium with plaque-associated Abeta, may represent additional DEA-extractable Abeta being liberated from beta-amyloid plaques over time in the brain. While brain APP is metabolized rapidly in both wild-type and an APP transgenic mice, our findings unexpectedly show that sAPP is more stable in vivo in the beta-amyloid containing Tg2576 brain when compared to wild-type mice. Additionally, the rapid turnover of a soluble pool of Abeta is similar in the wild-type and the Tg2576 mice in spite of the significant accumulation of plaque-associated Abeta in the brains of the transgenic mice. The slower turnover of sAPP in the mice with plaque pathology suggests that this neurotrophic APP metabolite may have an important role in the beta-amyloid containing brain.
###end p 24
###begin title 25
Materials and Methods
###end title 25
###begin title 26
Cycloheximide treatment
###end title 26
###begin p 27
###xml 190 194 190 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Hsiao1">[15]</xref>
###xml 441 445 437 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Gold1">[21]</xref>
###xml 698 719 682 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007134-g001">Figure 1B, 1E, 1F, 1G</xref>
###xml 724 726 708 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007134-g003">3A</xref>
###xml 970 979 954 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007134-g003">Figure 3B</xref>
###xml 26 30 <span type="species:ncbi:10090">mice</span>
###xml 143 147 <span type="species:ncbi:10090">mice</span>
###xml 179 184 <span type="species:ncbi:9606">human</span>
###xml 436 440 <span type="species:ncbi:10090">mice</span>
###xml 447 451 <span type="species:ncbi:10090">Mice</span>
###xml 803 807 <span type="species:ncbi:10090">mice</span>
###xml 855 859 <span type="species:ncbi:10090">mice</span>
###xml 898 903 <span type="species:ncbi:10090">mouse</span>
###xml 993 997 <span type="species:ncbi:10090">mice</span>
All experiments involving mice received prior approval from the Nathan Kline Institute Animal Care and Use Committee. Sixteen-month-old Tg2576 mice (overexpressing Swedish-mutant human APP) [15] and wild-type littermates on a Swiss Webster x DBA/C57BL6 F1 background were injected ip with 4.8 mg cycloheximide in 150 microl isotonic saline (containing 20 mM HEPES, pH 8), which has been shown to block protein synthesis in the brain of mice [21]. Mice were returned to their home cage, maintained at room temperature (22degreesC), sacrificed at the times indicated, and brain tissue was dissected and flash-frozen prior to storage at -80degreesC. The quantification of Western blot band density in Figure 1B, 1E, 1F, 1G and 3A is from two experiments with a total for both wild-type and Tg2576 of three mice at 0 and 23 hours cycloheximide treatment, two mice at 2, 4 and 6 hours treatment and one mouse at 1, 3, 5 and 7 hours treatment. In the tau experiments shown in Figure 3B, half of the mice were held in their home cage at a temperature of 34degreesC following cycloheximide injection.
###end p 27
###begin title 28
Cell cultures
###end title 28
###begin p 29
###xml 88 92 88 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Brewer1">[43]</xref>
###xml 465 469 461 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Mathews1">[44]</xref>
###xml 8 11 <span type="species:ncbi:10116">rat</span>
Primary rat neuronal cultures were established from E18 embryos as previously described [43], and maintained in Neurobasal Media (minus L-glutamine and phenol red) containing B27 supplement, penicillin-streptomycin and Gluta MAX-1 (all from Invitrogen, Carlsbad, CA) for 10 days. Primary neurons were treated with 40 microg of cycloheximide per 1 ml media for the times indicated prior to lysis and recovery of proteins for Western blotting as previously described [44].
###end p 29
###begin title 30
Antibodies
###end title 30
###begin p 31
###xml 127 131 127 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Mathews1">[44]</xref>
###xml 315 324 305 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007134.s001">Figure S1</xref>
###xml 731 735 705 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Nishitomi1">[45]</xref>
###xml 854 858 825 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-HirataFukae1">[46]</xref>
###xml 1178 1182 1149 1153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Otvos1">[47]</xref>
###xml 1328 1332 1299 1303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Qiu1">[11]</xref>
###xml 211 217 <span type="species:ncbi:10090">murine</span>
###xml 278 284 <span type="species:ncbi:10090">murine</span>
###xml 432 437 <span type="species:ncbi:9606">human</span>
###xml 442 448 <span type="species:ncbi:10090">murine</span>
###xml 544 549 <span type="species:ncbi:9606">human</span>
###xml 576 581 <span type="species:ncbi:9606">human</span>
###xml 593 599 <span type="species:ncbi:9986">Rabbit</span>
###xml 665 671 <span type="species:ncbi:10090">murine</span>
###xml 675 680 <span type="species:ncbi:9606">human</span>
###xml 741 746 <span type="species:ncbi:10090">mouse</span>
###xml 1295 1301 <span type="species:ncbi:9986">rabbit</span>
Antibodies C1/6.1 and m3.2 were generated in our laboratory: C1/6.1 recognizes the carboxyl-terminal cytoplasmic domain of APP [44], while the epitope for m3.2 has been determined to be within residues 10-15 of murine Abeta by mapping against synthetic peptides m3.2 recognizes murine APP, sAPPalpha and Abeta (See Figure S1). 22C11 was purchased from Millipore (Temecula, CA) and recognizes an N-terminal APP epitope common to the human and murine proteins. Monoclonal antibody 6E10 (Covance, Princeton, NJ), which recognizes residues 1-16 of human Abeta, was used to detect human sAPPalpha. Rabbit polyclonal anti-sAPPbeta antibody 242 recognizes only wild-type (murine or human) sAPPbeta but not Swedish-mutant-derived sAPPbeta [45], and mouse monoclonal antibody 6A1 recognizes sAPPbeta containing the Swedish mutation but not the wild-type sequence [46]. These sAPP antibodies (242, 6A1) recognize cleaved sAPP fragments and are not cross-reactive with uncleaved APP. Total tau protein was detected by a phosphate-independent anti-tau monoclonal antibody (Tau T57120; BD Bioscience, San Jose, CA). PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404 [47]. Neprilysin was detected with the monoclonal antibody 56C6 (CD10) (Novacastra, Newcastle, UK), and IDE with the rabbit polyclonal antibody IDE1 ([11]; a gift of Dr. Dennis Selkoe).
###end p 31
###begin title 32
Brain Processing, Western blotting, Detection of APP Metabolites
###end title 32
###begin p 33
###xml 198 202 198 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Schmidt1">[48]</xref>
Ten-percent (weight-to-volume) homogenates were prepared (in 250 mM sucrose, 20 mM Tris base, 1 mM EDTA, 1 mM EGTA and protease inhibitors) from hemibrains lacking the olfactory bulb and cerebellum [48], and these homogenates were subsequently used for Western blotting and extraction prior to Abeta sandwich ELISA. For Western blot analysis, membranes were incubated in the appropriate primary antibody (2 microg/ml) overnight and HRP-coupled secondary antibody for 1 hour.
###end p 33
###begin title 34
Abeta sandwich ELISAs
###end title 34
###begin p 35
###xml 222 226 216 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Schmidt1">[48]</xref>
###xml 523 527 499 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Rozmahel1">[49]</xref>
###xml 660 664 627 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Schmidt2">[50]</xref>
###xml 700 704 664 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Janus1">[51]</xref>
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
###xml 181 185 <span type="species:ncbi:10090">mice</span>
###xml 378 382 <span type="species:ncbi:10090">mice</span>
###xml 529 540 <span type="species:ncbi:3704">horseradish</span>
###xml 598 604 <span type="species:ncbi:10090">murine</span>
###xml 725 730 <span type="species:ncbi:9606">human</span>
###xml 751 756 <span type="species:ncbi:10090">mouse</span>
###xml 884 890 <span type="species:ncbi:10090">murine</span>
###xml 895 900 <span type="species:ncbi:9606">human</span>
Murine Abeta levels were determined by sandwich ELISA using aliquots of the 10% sucrose homogenate. Soluble Abeta from an aliquot of the sucrose homogenates of wild-type and Tg2576 mice was extracted by diethylamine (DEA) [48]; separately, formic-acid extraction of another aliquot of the sucrose homogenate was used to detect beta-amyloid plaque-associated Abeta in the Tg2576 mice. In combination with Abeta40 and Abeta42 C-terminal specific monoclonal antibodies (capture antibodies JRF/cAbeta40/10 and JRF/cAbeta42/26) [49], horseradish peroxidase-conjugated m3.2 was used to detect endogenous murine Abeta in Abeta40- and Abeta42-specific sandwich ELISAs [50]. Similar ELISAs using JRF/AbetaN25 [51] were used to detect human Abeta in the Tg2576 mouse brains. ELISA results are reported as the mean +/- SEM in fmol Abeta per g wet brain, based on standard curves using synthetic murine and human Abeta1-40 and Abeta1-42 peptide standards (American Peptide).
###end p 35
###begin title 36
Statistics
###end title 36
###begin p 37
Western blots were quantitated using ImageJ () and data analysis and graphs were plotted on GraphPad Prism v.5 (GraphPad Software, San Diego, CA, USA). Curve fitting and statistical two-way analysis of variance (ANOVA) were performed.
###end p 37
###begin title 38
Supporting Information
###end title 38
###begin p 39
###xml 463 467 437 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Mathews1">[44]</xref>
###xml 2478 2482 2391 2395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007134-Schmidt1">[48]</xref>
###xml 165 171 <span type="species:ncbi:10090">murine</span>
###xml 201 207 <span type="species:ncbi:10090">murine</span>
###xml 270 276 <span type="species:ncbi:10090">murine</span>
###xml 295 300 <span type="species:ncbi:9606">human</span>
###xml 396 402 <span type="species:ncbi:10090">murine</span>
###xml 415 420 <span type="species:ncbi:9606">human</span>
###xml 616 622 <span type="species:ncbi:10090">Murine</span>
###xml 687 693 <span type="species:ncbi:10090">murine</span>
###xml 703 708 <span type="species:ncbi:9606">human</span>
###xml 815 820 <span type="species:ncbi:9606">Human</span>
###xml 932 937 <span type="species:ncbi:9606">human</span>
###xml 942 948 <span type="species:ncbi:10090">murine</span>
###xml 993 998 <span type="species:ncbi:9606">Human</span>
###xml 1108 1113 <span type="species:ncbi:9606">human</span>
###xml 1157 1163 <span type="species:ncbi:10090">murine</span>
###xml 1221 1226 <span type="species:ncbi:9606">human</span>
###xml 1278 1283 <span type="species:ncbi:10090">mouse</span>
###xml 1399 1405 <span type="species:ncbi:10090">murine</span>
###xml 1453 1459 <span type="species:ncbi:10090">murine</span>
###xml 1498 1503 <span type="species:ncbi:10090">mouse</span>
###xml 1558 1563 <span type="species:ncbi:9606">human</span>
###xml 1630 1636 <span type="species:ncbi:10090">murine</span>
###xml 1671 1676 <span type="species:ncbi:10090">mouse</span>
###xml 1717 1722 <span type="species:ncbi:10090">mouse</span>
###xml 1780 1786 <span type="species:ncbi:10090">murine</span>
###xml 1820 1825 <span type="species:ncbi:10090">mouse</span>
###xml 1891 1897 <span type="species:ncbi:10090">murine</span>
###xml 1919 1924 <span type="species:ncbi:9606">human</span>
###xml 2005 2011 <span type="species:ncbi:10090">murine</span>
###xml 2015 2020 <span type="species:ncbi:9606">human</span>
###xml 2167 2173 <span type="species:ncbi:10090">murine</span>
###xml 2209 2214 <span type="species:ncbi:9606">human</span>
###xml 2266 2272 <span type="species:ncbi:10090">murine</span>
###xml 2296 2301 <span type="species:ncbi:10090">mouse</span>
###xml 2360 2365 <span type="species:ncbi:10090">mouse</span>
###xml 2373 2378 <span type="species:ncbi:10090">Mouse</span>
###xml 3018 3023 <span type="species:ncbi:10090">mouse</span>
Characterization of the monoclonal antibody m3.2. Antibody m3.2, which was generated in our laboratory against a synthetic peptide corresponding to residues 1-15 of murine Abeta, binds specifically to murine APP, sAPPalpha and Abeta. A. Specificity of m3.2 antibody for murine Abeta compared to human Abeta shown by immunoprecipitation and Western blotting. Equal amounts (3 microg) of synthetic murine Abeta42 and human Abeta42 were immunoprecipitated overnight [44] with m3.2 and 6E10 antibodies as indicated. The immunoprecipitate was resolved by SDS-PAGE, transferred to membrane, and probed with m3.2 antibody. Murine Abeta was detected in the m3.2 immunoprecipitation of synthetic murine Abeta42; human Abeta was not detected. IgG heavy and light chain reactivity is with the secondary detection antibody. B. Human Abeta was immunoprecipitated by antibody 6E10 and not detected by antibody m3.2. As was done in S1A, synthetic human and murine Abeta were immunoprecipitated as indicated. Human Abeta was immunoprecipitated and detected by antibody 6E10, while antibody m3.2 showed no reactivity for the human Abeta. C. Specificity of antibody m3.2 for murine APP metabolites. Western blotting using antibody m3.2 of human control and AD brain and wild-type and aged Tg2576 mouse brain is shown. Consistent with peptide mapping showing that the m3.2 antibody epitope is within residues 10-15 of murine Abeta (data not shown), antibody m3.2 detected murine APP and co-migrating sAPPalpha in the mouse brain extract, but did not detect any proteins in the human brain extracts. Additionally, antibody m3.2 detected the abundant murine Abeta co-deposited in aged Tg2576 mouse brain. D. Antibody m3.2 reactivity with mouse brain extract is blocked by co-incubation with synthetic murine Abeta. Wild-type and aged Tg2576 mouse brain extracts were resolved by SDS-PAGE as indicated. Synthetic murine Abeta42 or synthetic human Abeta was added to the antibody m3.2 binding solution as indicated (1 microg/ml murine or human Abeta, 2 microg/ml m3.2 antibody) 1 hour prior to membrane incubation. APP metabolites were not detected with the addition of competing synthetic murine Abeta42. The addition of synthetic human Abeta42 did not interfer with m3.2 reactivity with murine APP metabolites in the mouse brain. E. Antibody m3.2 detects both APP and sAPPalpha in mouse brain. Mouse brain homogenates were subjected to centrifugation at 100,000xg for 1 hour as previously described [48]. Equivalent amounts of the membrane pellet containing APP and the supernatant containing soluble sAPP were resolved by SDS-PAGE and probed with either antibody m3.2 or 22C11 as indicated. The subtle mobility shift in the smaller sAPP species is shown for sAPPalpha (m3.2) and total sAPP (22C11) compared to the membrane-associated APP in the pellet fractions. These Western blots also demonstrate the steady-state abundance of sAPPalpha (m3.2) and total sAPP (22C11) relative to APP, consistent with the slower turnover of sAPP in the mouse brain.
###end p 39
###begin p 40
(9.70 MB TIF)
###end p 40
###begin p 41
Click here for additional data file.
###end p 41
###begin p 42
###xml 513 518 <span type="species:ncbi:10090">mouse</span>
We would like to thank Dr. Dennis Selkoe (Harvard Medical School, Boston, MA, USA) for the gift of the anti-IDE antibody, Dr. Peter Davies (Albert Einstein College of Medicine, New York, NY, USA) for his gift of the anti-tau antibodies, Dr. Marc Mercken (Janssen, Beerse, Belgium) for anti-Abeta antibodies used in the ELISAs, Drs. Horikoshi-Sakuraba and Kinoshita (Immuno-Biological Laboratories, Takasaki, Japan) for anti-sAPP antibodies, Mr. Matthew Figliola and Dr. Monika Pawlik for their maintenance of the mouse colonies, and Dr. Ralph Nixon for reading this manuscript.
###end p 42
###begin title 43
References
###end title 43
###begin article-title 44
Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein.
###end article-title 44
###begin article-title 45
Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.
###end article-title 45
###begin article-title 46
Distinct sites of intracellular production for Alzheimer's disease Abeta40/42 amyloid peptides.
###end article-title 46
###begin article-title 47
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.
###end article-title 47
###begin article-title 48
beta-amyloid precursor protein cleavage by a membrane-bound protease.
###end article-title 48
###begin article-title 49
###xml 31 36 <span type="species:ncbi:9606">human</span>
Structure and functions of the human amyloid precursor protein: the whole is more than the sum of its parts.
###end article-title 49
###begin article-title 50
An endosomal-lysosomal pathway for degradation of amyloid precursor protein.
###end article-title 50
###begin article-title 51
Amyloid beta-peptide is produced by cultured cells during normal metabolism [see comments].
###end article-title 51
###begin article-title 52
Processing of the amyloid protein precursor to potentially amyloidogenic derivatives.
###end article-title 52
###begin article-title 53
Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition.
###end article-title 53
###begin article-title 54
Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation.
###end article-title 54
###begin article-title 55
Proteolytic processing and cell biological functions of the amyloid precursor protein.
###end article-title 55
###begin article-title 56
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life.
###end article-title 56
###begin article-title 57
###xml 36 41 <span type="species:ncbi:10090">mouse</span>
Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester.
###end article-title 57
###begin article-title 58
###xml 69 84 <span type="species:ncbi:10090">transgenic mice</span>
Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice [see comments].
###end article-title 58
###begin article-title 59
Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone.
###end article-title 59
###begin article-title 60
Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host.
###end article-title 60
###begin article-title 61
###xml 53 57 <span type="species:ncbi:10116">rats</span>
Effect of cycloheximide on temperature regulation in rats.
###end article-title 61
###begin article-title 62
Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer's disease.
###end article-title 62
###begin article-title 63
Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia.
###end article-title 63
###begin article-title 64
Retrograde amnesia produced by several treatments: evidence for a common neurobiological mechanism.
###end article-title 64
###begin article-title 65
###xml 39 54 <span type="species:ncbi:10090">transgenic mice</span>
Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology.
###end article-title 65
###begin article-title 66
###xml 158 165 158 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Three distinct axonal transport rates for tau, tubulin, and other microtubule-associated proteins: evidence for dynamic interactions of tau with microtubules in vivo.
###end article-title 66
###begin article-title 67
Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments.
###end article-title 67
###begin article-title 68
Microtubule-associated protein tau. A component of Alzheimer paired helical filaments.
###end article-title 68
###begin article-title 69
Familial Danish dementia: co-existence of Danish and Alzheimer amyloid subunits (ADan and Abeta) in the absence of compact plaques.
###end article-title 69
###begin article-title 70
###xml 59 74 <span type="species:ncbi:10090">transgenic mice</span>
AbetaPP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576.
###end article-title 70
###begin article-title 71
Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition.
###end article-title 71
###begin article-title 72
Amyloid precursor protein metabolism in primary cell cultures of neurons, astrocytes, and microglia.
###end article-title 72
###begin article-title 73
Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport.
###end article-title 73
###begin article-title 74
Post-translational processing and turnover kinetics of presynaptically targeted amyloid precursor superfamily proteins in the central nervous system.
###end article-title 74
###begin article-title 75
###xml 83 86 <span type="species:ncbi:10116">rat</span>
Postnatal development of bulk flow in the cerebrospinal fluid system of the albino rat: clearance of carboxyl-(14 C) inulin after intrathecal infusion.
###end article-title 75
###begin article-title 76
###xml 26 31 <span type="species:ncbi:10090">mouse</span>
Clearance of albumin from mouse subarachnoid space: a measure of CSF bulk flow.
###end article-title 76
###begin article-title 77
Trophic effect of beta-amyloid precursor protein on cerebral cortical neurons in culture.
###end article-title 77
###begin article-title 78
Activation of K+ channels and suppression of neuronal activity by secreted beta-amyloid-precursor protein.
###end article-title 78
###begin article-title 79
Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein.
###end article-title 79
###begin article-title 80
Secreted forms of beta-amyloid precursor protein modulate dendrite outgrowth and calcium responses to glutamate in cultured embryonic hippocampal neurons.
###end article-title 80
###begin article-title 81
Increase of synaptic density and memory retention by a peptide representing the trophic domain of the amyloid beta/A4 protein precursor.
###end article-title 81
###begin article-title 82
###xml 174 178 <span type="species:ncbi:10090">mice</span>
The secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice.
###end article-title 82
###begin article-title 83
New insights into brain BDNF function in normal aging and Alzheimer disease.
###end article-title 83
###begin article-title 84
Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production.
###end article-title 84
###begin article-title 85
Release of excess amyloid beta protein from a mutant amyloid beta protein precursor [see comments].
###end article-title 85
###begin article-title 86
Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination.
###end article-title 86
###begin article-title 87
Calpain activity regulates the cell surface distribution of amyloid precursor protein: inhibition of calpains enhances endosomal generation of beta-cleaved C-terminal APP fragments.
###end article-title 87
###begin article-title 88
###xml 81 85 <span type="species:ncbi:10090">mice</span>
BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice.
###end article-title 88
###begin article-title 89
Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model.
###end article-title 89
###begin article-title 90
Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404.
###end article-title 90
###begin article-title 91
Tissue processing prior to protein analysis and amyloid-beta quantitation.
###end article-title 91
###begin article-title 92
###xml 44 48 <span type="species:ncbi:10090">mice</span>
Normal brain development in PS1 hypomorphic mice with markedly reduced gamma-secretase cleavage of betaAPP.
###end article-title 92
###begin article-title 93
ELISA method for measurement of amyloid-beta levels.
###end article-title 93
###begin article-title 94
Abeta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease.
###end article-title 94
###begin article-title 95
Differential turnover of tubulin and neurofilament proteins in central nervous system neuron terminals.
###end article-title 95
###begin p 96
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 96
###begin p 97
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by the NIH (NS045205 (PM), AG017617 (EL and PM), AG022455 (YM)) and Alzheimer's Association (IIRG-07-60047;PM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 97

